CD4 and neoplasm: The increased CTL activities are prevented by CD8 monoclonal antibodies, and partly abrogated by CD4 or NK monoclonal antibodies, indicating its killing activity against tumor may be associated with the activation of CD4+T, CD8+ T and NK cells (Figure 6C and 6D).